Candriam SCA’s Myriad Genetics MYGN Stock Holding History

Candriam SCA’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-45,398	Closed	-$659K	–	910
2022 Q4	$659K	Buy	45,398 +1,241	+3%	+$23.1K	﹤0.01%	772
2022 Q3	$843K	Buy	+44,157	New	+$1.01M	0.01%	749
2019 Q2	–	Sell	-131,732	Closed	-$4.37M	–	829
2019 Q1	$4.37M	Buy	+131,732	New	+$4.01M	0.06%	354
2017 Q2	–	Sell	-74,000	Closed	-$1.42M	–	716
2017 Q1	$1.42M	Hold	74,000	–	–	0.03%	505
2016 Q4	$1.23M	Buy	+74,000	New	+$1.34M	0.03%	478

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Candriam SCA's MYGN Position: Q1 2023 in Review

Candriam SCA sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 45,398 shares — an estimated $659K sold.

Candriam SCA first reported a position in MYGN in Q4 2016 and held it in 5 quarters. The position peaked at $4.37M in Q1 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

Candriam SCA reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
Candriam SCA sold 45,398 Myriad Genetics shares in Q1 2023, an estimated $659K.
Candriam SCA first reported a position in Myriad Genetics in Q4 2016 and held it in 5 quarters.
Candriam SCA's Myriad Genetics position peaked at $4.37M in Q1 2019.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.